NTRK2 and osteosarcoma: Receptor−biased modulation may provide finer control of neurotrophin signaling: small−molecule TrkB/TrkC ligands from the neurodegeneration field demonstrate tractable pharmacology and pathway selectivity, motivating preclinical testing for microenvironmental and immune consequences in osteosarcoma.